Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02810327 · ClinicalTrials.gov registry record

Alpha-1 Carrier Genomics Study

A clinical trial of Smoking and COPD, sponsored by Medical University of South Carolina.

Completed
Registry status
117
Enrollment target
1
Study location

NCT02810327: Completed study of Smoking and COPD, sponsored by Medical University of South Carolina.

NCT02810327 is a study of Smoking and COPD that has completed, run by Medical University of South Carolina. The registered enrollment target is 117 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02810327, a study of Smoking and COPD, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
117 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ) individuals develop chronic obstructive pulmonary disease (COPD) while others do not. This study will examine portions of the Alpha-1 gene that are not routinely tested to determine whether other changes in this gene correlate with development and progression of COPD. Participation involves responding to questionnaires about lung health and history, and performing an at-home finger stick to obtain blood spots using a test kit that is mailed. The blood provided will be used for genetic testing and correlation of results with COPD history. Participants will receive their results and access to genetic counseling at the conclusion of the study.

Primary Outcome

Additional SERPINA1 variant of known or possible significance detected by next generation sequencing.

Interventions

  • GENETIC Genetic Sequencing

Study Locations (1)

South Carolina

  • Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine - Charleston

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2015-02
Est. Completion 2017-04

What the finished NCT02810327 record still lists

NCT02810327 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower).

The record links to 4 conditions, with Smoking appearing as the primary indexed condition, and to 1 intervention - of which Genetic Sequencing is the first listed.

NCT02810327 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT02810327 about?

NCT02810327 is a clinical study titled "Alpha-1 Carrier Genomics Study". The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ) individuals develop chronic obstructive pulmonary disease (COPD) while others do not. This study will examine portions of the Alpha-1 gene that are not routinely tested to determine whether other changes in this gene ...

What is the current status of trial NCT02810327?

This trial is currently completed. The enrollment target is 117 participants. The study started on 2015-02. Estimated completion is 2017-04.

What conditions does trial NCT02810327 study?

This clinical trial studies the following conditions: Smoking, COPD, Emphysema, Alpha-1 Antitrypsin Deficiency.

What interventions are being tested in trial NCT02810327?

The interventions under investigation include: Genetic Sequencing (GENETIC).

Who is sponsoring clinical trial NCT02810327?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02810327 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02810327's enrollment target sits among peer trials

117 66th of 123 higher than 57 of 123 other Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02810327, the US trial registry maintained by the National Library of Medicine. NCT02810327 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.